Neurocrine Biosciences Files Second Quarter 10-Q With SEC
The San Diego-based biopharmaceutical company submitted its quarterly report to regulators as insider transactions draw investor attention.
Quarterly Filing Submitted
Neurocrine Biosciences, Inc. (NBIX) filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on July 31, according to SEC EDGAR filings. The submission provides the company's financial and operational disclosures for the second quarter of 2026.
The San Diego-based biopharmaceutical company, with a market capitalization of approximately $19 billion, closed at $185.50 per share as of its last reported trading session.
Recent Insider Activity
Recent insider transactions have been recorded at the company, according to MarginX data. Leslie V. Norwalk, a company insider, executed multiple stock options exercises totaling 1,684 shares across two separate transactions. Norwalk subsequently sold 1,250 shares, representing a partial monetization of the exercised options.
While insider transactions occur for various personal financial planning reasons, market participants often monitor such activity as part of their broader assessment of corporate developments.
Looking Ahead
Investors will have several key dates to monitor in the coming months. The Federal Reserve is scheduled to announce its next interest rate decision and economic projections on September 16, 2026, followed by another FOMC decision on October 28, according to MarginX data.
Neurocrine Biosciences is expected to report its third-quarter 2026 financial results on October 30, 2026, which will provide updated guidance and operational metrics approximately three months from the current quarterly filing.
The 10-Q filing is a standard regulatory requirement for publicly traded companies, providing unaudited financial statements and a comprehensive overview of business operations, risk factors, and management's discussion and analysis of financial condition and results of operations.
Neurocrine Biosciences specializes in treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's quarterly disclosures are closely watched by investors seeking insight into commercial performance, pipeline developments, and strategic direction.
This article was generated by MarginX from public news on 2026-07-31. It is not investment advice.